Dianthus Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DNTH research report →
Companydianthustx.com
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
- CEO
- Marino Garcia
- IPO
- 2018
- Employees
- 78
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $3.70B
- P/E
- -376.35
- P/S
- 2772.50
- P/B
- 3.55
- EV/EBITDA
- -16.43
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 94.31%
- Op Margin
- -14318.04%
- Net Margin
- -847.53%
- ROE
- -1.78%
- ROIC
- -15.82%
Growth & Income
- Revenue
- $2.04M · -67.35%
- Net Income
- $-162,337,000 · -91.05%
- EPS
- $-4.20 · -64.71%
- Op Income
- $-177,933,000
- FCF YoY
- -65.13%
Performance & Tape
- 52W High
- $96.50
- 52W Low
- $16.64
- 50D MA
- $85.78
- 200D MA
- $50.92
- Beta
- 0.09
- Avg Volume
- 950.71K
Get TickerSpark's AI analysis on DNTH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | Soteropoulos Paula | other | 599 |
| May 8, 26 | Soteropoulos Paula | sell | 599 |
| May 8, 26 | Soteropoulos Paula | other | 599 |
| Apr 9, 26 | Savitz Ryan | other | 8,224 |
| Apr 9, 26 | Savitz Ryan | other | 8,224 |
| Apr 9, 26 | Savitz Ryan | sell | 8,224 |
| Mar 31, 26 | Savitz Ryan | other | 40,000 |
| Mar 31, 26 | Savitz Ryan | sell | 1,390 |
| Mar 31, 26 | Savitz Ryan | sell | 21,825 |
| Mar 31, 26 | Savitz Ryan | sell | 1,485 |
Our DNTH Coverage
We haven't published any research on DNTH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DNTH Report →